Protagonist Therapeutics (PTGX) operating margin

Operating margin · fiscal 2025
-343.6%

Protagonist Therapeutics (PTGX) had an operating margin of -343.6% in fiscal 2025 (the year ended December 31, 2025). That is 401.8 percentage points lower than the 58.2% of fiscal 2024. Figures as of 17 Nov 2026, 23:22 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Operating margin, fiscal 2025
-343.6%
Change on fiscal 2024
−401.8 pts
Highest on record
58.2%fiscal 2024
Lowest on record
-34857.6%fiscal 2019
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Protagonist Therapeutics operating margin, in more detail

Across the 9 fiscal years on record (2017–2025), the highest was 58.2% in fiscal 2024 and the lowest -34857.6% in fiscal 2019. The fiscal 2025 figure is higher than in 38% of the 8 earlier fiscal years on record, whose median is -207.1%.

Net margin was -282.8% in fiscal 2025.

History · 9 fiscal years

Operating margin by fiscal year

  • Operating margin
  • Net margin

Protagonist Therapeutics operating margin, year by year

Protagonist Therapeutics (PTGX) operating margin by fiscal year
Fiscal yearOperating marginChangeYear endedNet margin
2025-343.6% 401.8 pts down-282.8%
202458.2% 214.3 pts up63.3%
2023-156.1% 338.1 pts up-131.6%
2022-494.2% 34.2 pts down-479.3%
2021-460.0% 234.7 pts down-458.9%
2020-225.4% 34632.2 pts up-231.1%
2019-34857.6% 34720.9 pts down-33414.3%
2018-136.7% 52.2 pts up-125.9%
2017-188.9%—-184.2%

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

How to read it

It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.

Operating margin at health care companies of similar size

Operating margin of Protagonist Therapeutics and comparable companies
CompanyOperating marginFiscal year
Praxis Precision Medicines PRAX-2340.3%2024
Twist Bioscience TWST-36.2%2025
Protagonist Therapeutics PTGX-343.6%2025
Krystal Biotech KRYS41.5%2025
10x Genomics TXG-17.2%2025
HealthEquity HQY24.9%2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PTGX

Protagonist Therapeutics, figure by figure

Protagonist Therapeutics (PTGX) overview: price, valuation and scorecardAll health care companies by market value

Protagonist Therapeutics operating margin: questions and answers

What is Protagonist Therapeutics's operating margin?

Protagonist Therapeutics (PTGX) had an operating margin of -343.6% in fiscal 2025 (the year ended December 31, 2025). That is 401.8 percentage points lower than the 58.2% of fiscal 2024.

Is Protagonist Therapeutics's operating margin high or low compared with its own history?

The fiscal 2025 figure is higher than in 38% of the 8 earlier fiscal years on record, whose median is -207.1%.

What are the highest and lowest operating margin figures on record for Protagonist Therapeutics?

Across the 9 fiscal years on record (2017–2025), the highest was 58.2% in fiscal 2024 and the lowest -34857.6% in fiscal 2019.

What are Protagonist Therapeutics's gross and net margins?

Net margin was -282.8% in fiscal 2025.

How is Protagonist Therapeutics's operating margin calculated?

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Protagonist Therapeutics (PTGX) operating margin”, data as of 17 November 2026. https://funkfolio.com/stock/PTGX/operating-margin

Underlying data: the company's filings with the SEC and Yahoo Finance.